Intelligence Feed event · Equity · 2026-09-25

    ADARx Pharmaceuticals prices upsized $446.3M initial public offering at $17 per share

    Question

    ADARx Pharmaceuticals prices upsized $446.3M initial public offering at $17 per share

    Direct answer

    ADARx Pharmaceuticals finalized an upsized initial public offering of 26.25 million shares at $17 per share, raising $446.3 million. The clinical-stage company is focused on advancing siRNA platforms. The transaction provides a fresh data point for equity capital markets liquidity in the healthcare and biotechnology sector.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-25
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “ADARx Pharmaceuticals prices upsized $446.3M initial public offering at $17 per share”, revision 1, evidence through 2026-09-25. https://marketontology.com/market-events/2026-09-25/adarx-pharmaceuticals-prices-upsized-446-3m-initial-public-offering-at-17-per-sh-e9454a

    EQUITY
    ADARx Pharmaceuticals prices upsized $446.3M initial public offering at $17 per share
    ADARx Pharmaceuticals finalized an upsized initial public offering of 26.25 million shares at $17 per share, raising $446.3 million. The clinical-stage company is focused on advancing siRNA platforms. The transaction provides a fresh data point for equity capital markets liquidity in the healthcare and biotechnology sector.
    ADRX
    Impact
    66
    SEP 25
    SIG
    95%
    ADRX
    ADARx Pharmaceuticals prices upsized $446.3M initial public offering at $17 per share
    ADARx Pharmaceuticals finalized an upsized initial public offering of 26.25 million shares at $17 per share, raising $446.3 million. The clinical-stage company is focused on advancing siRNA platforms. The transaction provides a fresh data point for equity capital markets liquidity in the healthcare and biotechnology sector.
    → Upsized clinical biotech IPO pricing indicates receptive institutional demand for late-stage siRNA therapeutic pipelines.
    Impact
    ADARx Pharmaceuticals finalized an upsized initial public offering of 26.25 million shares at $17 per share, raising $446.3 million. The clinical-stage company is focused on advancing siRNA platforms. The transaction provides a fresh data point for equity capital markets liquidity in the healthcare and biotechnology sector.
    Affected
    ADRX
    Transmission
    Upsized clinical biotech IPO pricing indicates receptive institutional demand for late-stage siRNA therapeutic pipelines.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    ADRXdebut secondary market liquidity and balance sheet capitalizationUpintradayTrading begins on Nasdaq on September 25, 2026 under ticker ADRX.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    ADRXUpdisagreed19.35 2026-09-25+3.82%-5.68%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month